JPRN-jRCT2080221565未知3 期
Open-label study of TAK-875
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点开始时间: 2011年9月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. The subject is an outpatient.
- •2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- •2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
研究者
相似试验
未知
3 期
ong-term study of TAK-875Diabetes mellitusJPRN-jRCT2080221562TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
1 期
A Phase 1 study of TAK-385 in Patients With Androgen Deprivation Treatment-Naive Prostate CancerJPRN-jRCT2080222485TAKEDA PHARMACEUTICAL COMPANY LTD.43
未知
2 期
A Phase 2, Open-label, Single-arm Study of TAK-700 (orteronel) in Patients With Nonmetastatic Castration-resistant Prostate Cancer and Rising Prostate-specific AntigeJPRN-jRCT2080221969Takeda Pharmaceutical Company Limited30
未知
3 期
Double-blind comparative study of TAK-875Diabetes mellitusJPRN-jRCT2080221564TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
Double-blind comparative study of TAK-875Diabetes mellitusJPRN-jRCT2080221774TAKEDA PHARMACEUTICAL COMPANY LTD.